Form 4: Cognition Therapeutics CFO John Brendan Doyle Reports Tax Withholding Transaction
SEC Form 4 Filing
John Brendan Doyle, CFO of Cognition Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On May 1, 2025, John Brendan Doyle, the Chief Financial Officer of Cognition Therapeutics Inc. (CGTX), reported a transaction on SEC Form 4.
- The transaction involved the withholding of 9,692 shares of common stock by the issuer to cover tax withholding obligations related to the vesting of restricted stock units.
- The price per share for the withholding was $0.4472.
- Following the transaction, Doyle directly owns 404,710 shares of Cognition Therapeutics Inc.
Sentiment
Score: 5
Explanation: This is a neutral transaction related to tax withholding, so it doesn't indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of compliance for corporate insiders and provide transparency into their transactions in company stock. This transaction is related to tax obligations arising from the vesting of restricted stock units, a common form of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 05/01/2025 | Date of transaction involving tax withholding. |
| 05/02/2025 | Date of signature on the SEC Form 4 filing. |
Keywords
Form 4, Cognition Therapeutics, CGTX, John Brendan Doyle, CFO, Tax Withholding, Restricted Stock Units, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.